In a groundbreaking achievement, Apex Hospitals has become India’s first cancer care centre to administer the innovative immunotherapy drug Toripalimab to a patient battling Stage IV nasopharyngeal carcinoma, a rare and aggressive type of head and neck cancer. This marks a significant milestone in the country’s fight against advanced cancers.

Previously available only in the United States and China, Toripalimab has been successfully introduced in India under the expert guidance of Dr. Pulkit Nag, a renowned Medical Oncologist at Apex Hospitals, Jaipur. The patient, treated with this cutting-edge therapy, showed remarkable improvement and was discharged without adverse side effects.

Speaking about the achievement, Dr. Nag explained, “This year, Toripalimab was specifically developed by Dr. Reddy for patients with nasopharyngeal carcinoma. Its exclusive focus on this cancer subtype has already shown promising results globally. At Apex Hospitals, we are proud to be the first in the country to make this life-saving treatment available.”

Dr. Pulkit Nag, one of the most trusted oncologists in Malviya Nagar, Jaipur, specializes in medical oncology, including treating various cancers affecting the blood, liver, pancreas, mouth, and lungs. His dedication to patient care and a thorough understanding of advanced systemic treatments have positioned Apex Hospitals as a leader in cancer care.

This landmark treatment underscores Apex Hospitals’ commitment to offering cutting-edge medical advancements to its patients. With state-of-the-art facilities and a compassionate approach, the hospital continues to raise the standard of healthcare in India.

The success of Toripalimab at Apex Hospitals brings new hope to cancer patients and cements the hospital’s reputation as a pioneer in medical oncology and immunotherapy treatments.